| Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden Z Younossi, H Park, L Henry, A Adeyemi, M Stepanova Gastroenterology 150 (7), 1599-1608, 2016 | 274 | 2016 |
| Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection ZM Younossi, H Park, S Saab, A Ahmed, D Dieterich, SC Gordon Alimentary pharmacology & therapeutics 41 (6), 544-563, 2015 | 131 | 2015 |
| Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis H Park, C Park, Y Kim, KL Rascati Annals of Pharmacotherapy 46 (11), 1453-1469, 2012 | 123 | 2012 |
| A meta‐analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection H Park, A Adeyemi, L Henry, M Stepanova, Z Younossi Journal of viral hepatitis 22 (11), 897-905, 2015 | 84 | 2015 |
| Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection S Saab, SC Gordon, H Park, M Sulkowski, A Ahmed, Z Younossi Alimentary pharmacology & therapeutics 40 (6), 657-675, 2014 | 79 | 2014 |
| Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C ZM Younossi, H Park, SC Gordon, JR Ferguson, A Ahmed, D Dieterich, ... Am J Manag Care 22 (6), SP205-11, 2016 | 56 | 2016 |
| Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism … GK Dawwas, J Brown, E Dietrich, H Park The Lancet Haematology 6 (1), e20-e28, 2019 | 43 | 2019 |
| Evaluation of health care costs and utilization patterns for patients with gout H Park, KL Rascati, K Prasla, T McBayne Clinical therapeutics 34 (3), 640-652, 2012 | 43 | 2012 |
| Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD H Park, C Chen, W Wang, L Henry, RL Cook, DR Nelson Hepatology 67 (2), 492-504, 2018 | 40 | 2018 |
| Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase H Park, KL Rascati, KA Lawson, JC Barner, KM Richards, DC Malone Journal of Managed Care Pharmacy 20 (8), 862-876, 2014 | 37 | 2014 |
| Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care ZM Younossi, H Park, D Dieterich, S Saab, A Ahmed, SC Gordon Medicine 95 (41), 2016 | 32 | 2016 |
| Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes GK Dawwas, SM Smith, H Park Diabetes, Obesity and Metabolism 21 (1), 28-36, 2019 | 31 | 2019 |
| The value of cure associated with treating treatment‐naïve chronic hepatitis C genotype 1: Are the new all‐oral regimens good value to society? ZM Younossi, H Park, D Dieterich, S Saab, A Ahmed, SC Gordon Liver International 37 (5), 662-668, 2017 | 24 | 2017 |
| Direct medical costs and utilization of health care services to treat pneumonia in the United States: an analysis of the 2007–2011 Medical Expenditure Panel Survey H Park, AO Adeyemi, KL Rascati Clinical therapeutics 37 (7), 1466-1476. e1, 2015 | 23 | 2015 |
| Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective H Park, KL Rascati, MS Keith, P Hodgkins, M Smyth, D Goldsmith, ... Value in Health 14 (8), 1002-1009, 2011 | 23 | 2011 |
| Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States H Park, W Wang, L Henry, DR Nelson Hepatology 69 (3), 1032-1045, 2019 | 21 | 2019 |
| Cost-effectiveness of expanded newborn screening in Texas SK Tiwana, KL Rascati, H Park Value in Health 15 (5), 613-621, 2012 | 21 | 2012 |
| Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity‐matched cohort study H Park, GK Dawwas, X Liu, MH Nguyen Journal of Internal Medicine 286 (6), 711-722, 2019 | 18 | 2019 |
| Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists GK Dawwas, SM Smith, H Park Cardiovascular diabetology 17 (1), 102, 2018 | 13 | 2018 |
| Scales of smoking-related self-efficacy, beliefs, and intention: assessing measurement invariance among intermittent and daily high school smokers KL Sterling, KH Ford, H Park, AL McAlister American Journal of Health Promotion 28 (5), 310-315, 2014 | 12 | 2014 |
